J&J's R&D successes earn some respect on Wall Street; AstraZeneca starts hatcheting positions in cutback; Is GSK plotting a hike in HGS bid?

@FierceBiotech: The ethics of finding markers in a fetal genome. Commentary | Follow @FierceBiotech

@JohnCFierce: Novartis is going to invest $700M in Malaysian biotechs? Really? Report | Follow @JohnCFierce

@RyanMFierce: Sequoia-backed startup enters race to make sense of the genome. Article | Follow @RyanMFierce

> JP Morgan analyst Michael Weinstein has handed an upgrade to J&J ($JNJ), which earned some respect for its R&D successes, including the approval of Zytiga. Report

> AstraZeneca ($AZN) said it was going to cut 7,300 more jobs and that is what it has started doing. In Sweden, that means 400 jobs, mostly administrative, with a majority coming from a facility in Södertälje, reports The Local. The cuts follow negotiations with the union, the paper says. Report

> Some prominent analysts are speculating that GlaxoSmithKline ($GSK) may be on the verge of increasing its bid for Human Genome Sciences ($HGSI), even though no rival bidder has appeared to spark an auction. Story

> A new venture fund called Select BioVentures is out trying to raise $200 million to invest in Florida life science companies. Report

> Astex Pharmaceuticals in the U.K. won a $5.4 million milestone after J&J's Janssen got the green light for a Phase I study of their Fibroblast Growth Factor Receptor (FGFR) kinase inhibitor. Story

Pharma News

@FiercePharma: Here's an offbeat pharma story: Sanofi's investor relations team won the prize in a Thomson Reuters financial contest--Reuters. Report | Follow @FiercePharma

> Drugstores accuse Pfizer, Teva of blocking Effexor generics. Report

> Are the dog days over for Johnson & Johnson? More

> Big Pharma's Japanese sales gain as U.S., Europe lag. Story

Medical Devices News

@FierceMedDev: Advanced diagnostic imaging use has grown drastically, boosting radiation exposure risks, a new JAMA study concludes. More | Follow @FierceMedDev

@MarkHFierce: Seventh Sense Biosystems raises $10M Series A and brings on a new CEO to help develop its blood sampling system. Release | Follow @MarkHFierce

> CMS to pare back Medicare coverage for low back pain treatment-devices. More

> Brigham Young engineers create next-gen spinal disc implant. Story

> St. Jude stock nosedives after reported Durata lead flaw. News

Drug Delivery News

@DamianFierce: One U.K. company is developing a chocolate-based drug delivery platform, and NIH has taken notice. Story | Follow @DamianFierce

> Zogenix signs co-promotion deal for needle-free migraine treatment. More

> Allergan looks to needle-free delivery for Botox. More

> J&J moves forward with next-gen insulin delivery. Item

Biomarkers News

> Cluster of genes is biomarker for breast cancer recurrence. Story

> Methylation marker tags leukemia outcomes. Article

> Gene signatures tag breast cancer drug response. News

> Scientists detect Down syndrome using mother's blood. More

And Finally… Investigators at the Boston University School of Medicine say they've identified a novel new set of proteins that build up in the brains of Alzheimer's victims, a development that may point to a new biomarker for the disease. Release


Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.